November 2021

Discover ETAP-Lab and other biotech businesses at an Afterwork evening on November 18th, organised by Biovalley France. Nicolas Violle will be delighted to meet you and tell you about what we do at ETAP-Lab. A rare opportunity to connect with key players in the Lorraine region. Thanks to BioValley France for making it happen!

Hypo-excitability was reported in the peri-infarct tissue following stroke, an effect counteracted by a blockage of α5-GABAA receptors in adult rodents. Our present study aims to evaluate the effect of a selective α5-GABAA receptor antagonist, S 44819, in stroke in juvenile animals. We have set up and characterized an original model of transient ischemic stroke in 28 day-old Sprague-Dawley rats (45-min occlusion of the middle cerebral artery by intraluminal suture). In this model, S 44819 (1, 3 and 10 mg/kg,

Invisible but devastating, diabetes is a chronic disease affecting more than 463 million adults worldwide; it results in more than 1.5 million deaths each year. The number of patients is expected to reach 700 million by 2045 - so treating diabetes and its complications really is a major health challenge! On this day of solidarity and awareness, ETAP-Lab would like to show its support for diabetic patients. At ETAP-Lab, we’re already involved in fighting back against diabetes — our work on developing

Renewal of ETAP-Lab’s ISO 9001 certification (v2015)! A well-managed quality system is key to a high performance, trustworthy preclinical service. ETAP-Lab has been investing in quality management continuously for almost 10 years now. And for 10 years, ISO 9001 certification has recognized the excellence of our quality management system in the areas of consultancy and expertise as well as in the conduct of in vitro and in vivo preclinical research studies. Because we are always scrupulous in carrying out and monitoring our